Teladoc Health, Inc. to Post FY2024 Earnings of ($1.00) Per Share, Cantor Fitzgerald Forecasts (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOCFree Report) – Cantor Fitzgerald issued their FY2024 earnings estimates for Teladoc Health in a research note issued to investors on Monday, April 29th. Cantor Fitzgerald analyst S. James anticipates that the health services provider will earn ($1.00) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $22.00 price target on the stock. The consensus estimate for Teladoc Health’s current full-year earnings is ($1.04) per share.

Other equities analysts also recently issued research reports about the company. SVB Leerink started coverage on Teladoc Health in a research report on Monday, February 26th. They set a “market perform” rating and a $17.00 price target on the stock. DA Davidson dropped their price target on Teladoc Health from $22.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 21st. Wells Fargo & Company reduced their price objective on shares of Teladoc Health from $17.00 to $15.00 and set an “equal weight” rating for the company in a research report on Monday. Evercore ISI dropped their price objective on shares of Teladoc Health from $15.00 to $14.00 and set an “in-line” rating on the stock in a research report on Friday, April 26th. Finally, Canaccord Genuity Group reduced their target price on shares of Teladoc Health from $28.00 to $25.00 and set a “buy” rating for the company in a report on Friday, April 26th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Teladoc Health currently has an average rating of “Hold” and a consensus target price of $18.73.

View Our Latest Stock Report on TDOC

Teladoc Health Trading Up 1.4 %

Shares of Teladoc Health stock opened at $13.00 on Wednesday. The stock has a market cap of $2.20 billion, a P/E ratio of -9.22 and a beta of 0.97. The company has a quick ratio of 3.47, a current ratio of 3.82 and a debt-to-equity ratio of 0.67. Teladoc Health has a 12-month low of $12.53 and a 12-month high of $30.41. The business’s 50 day moving average is $14.48 and its 200-day moving average is $17.60.

Teladoc Health (NYSE:TDOCGet Free Report) last posted its earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.13%. The business had revenue of $646.13 million during the quarter, compared to analyst estimates of $637.31 million. During the same period in the previous year, the firm posted ($0.37) earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis.

Insider Transactions at Teladoc Health

In related news, insider Daniel Trencher sold 6,780 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $98,445.60. Following the completion of the transaction, the insider now owns 28,192 shares in the company, valued at $409,347.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Daniel Trencher sold 6,780 shares of Teladoc Health stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $98,445.60. Following the sale, the insider now directly owns 28,192 shares in the company, valued at $409,347.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew Turitz sold 6,190 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $89,878.80. Following the completion of the transaction, the executive vice president now owns 39,429 shares of the company’s stock, valued at $572,509.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 138,368 shares of company stock worth $1,989,227. Company insiders own 0.95% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in TDOC. ICA Group Wealth Management LLC bought a new position in Teladoc Health in the 4th quarter worth approximately $28,000. Hexagon Capital Partners LLC grew its stake in shares of Teladoc Health by 204.4% during the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after buying an additional 1,065 shares during the last quarter. RIA Advisory Group LLC purchased a new stake in shares of Teladoc Health during the fourth quarter valued at $36,000. GAMMA Investing LLC bought a new stake in shares of Teladoc Health during the fourth quarter valued at approximately $41,000. Finally, Principal Securities Inc. purchased a new stake in shares of Teladoc Health in the 4th quarter worth $45,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

About Teladoc Health

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

See Also

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.